Clik here to view.
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in...
TOKYO & BASKING RIDGE, N.J. & MUNICH Detailed results from the positive pivotal randomized, controlled phase 2 DESTINY-Gastric01 trial showed Daiichi Sankyo Company, Limited (hereafter,...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has...
View ArticleClik here to view.
Harbour BioMed Receives Chinese Regulatory Approval of IND Application to...
CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SUZHOU, China Harbour BioMed (HBM) today announced that National Medical Products Administration (NMPA, China) approved its IND application...
View ArticleClik here to view.
Fibralign Announces Strategic Partnership With Terumo
UNION CITY, Calif. Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced today that it has executed a long term distributor agreement with Terumo...
View ArticleClik here to view.
武田发布Pevonedistat联合阿扎胞苷治疗较高危MDS患者2期试验的有力数据
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View ArticleClik here to view.
武田薬品、高リスクMDS患者でpevonedistatとアザシチジンの併用療法を検討する第2相試験の有力なデータを発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has...
View ArticleClik here to view.
Noxopharm Reports Veyonda’s Potential in Late-Stage Cancer at ASCO 2020
SYDNEY At the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, Noxopharm, a clinical-stage Australian oncology drug development company, has reported two sets of clinical...
View ArticleClik here to view.
New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 HELP (Hereditary Angioedema...
View ArticleClik here to view.
Genetron Health Receives FDA Emergency Use Authorization for SARS-CoV-2 RNA...
BEIJING Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, announced that its independently developed detection kit for the...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has...
View ArticleClik here to view.
Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting...
DAEJEON, South Korea Alteogen Inc. (KOSDAQ:196170) has today presented at ASCO results from the First-in-Human (FIH), phase 1 study of ALT-P7, a HER2-targeting antibody-drug conjugate (ADC), in...
View ArticleClik here to view.
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral...
View ArticleClik here to view.
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in...
TOKYO & BASKING RIDGE, N.J. & MUNICH Detailed results from the positive pivotal randomized, controlled phase 2 DESTINY-Gastric01 trial showed Daiichi Sankyo Company, Limited (hereafter,...
View ArticleClik here to view.
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration agreement with a subsidiary...
View ArticleClik here to view.
HitGen and Evotec SE Enter Into Drug Discovery Research Collaboration
CHENGDU, China HitGen (688222.SH) today announced that it has entered into a drug discovery research collaboration with Evotec SE to identify small molecule leads against targets of interest to...
View ArticleClik here to view.
Promega Microsatellite Instability Molecular Test, OncoMate™ MSI Dx Analysis...
LEIDEN, Netherlands & MADISON, Wis. Promega Corporation today announced CE marking for the OncoMate™ MSI Dx Analysis System (OncoMate™ MSI) as a new in vitro diagnostic (IVD) medical device in...
View ArticleClik here to view.
CANbridge Pharmaceuticals Enters Into Rare Disease Gene Therapy Research...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions, announced that it has...
View ArticleClik here to view.
Lyvgen Announces Clinical Trial Collaboration With MSD
SHANGHAI Lyvgen, a biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, announces that it has entered into a clinical trial collaboration agreement with a...
View ArticleClik here to view.
Personalis Announces a Partnership with Berry Genomics for China Expansion
MENLO PARK, Calif. Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced the partnership with Berry Genomics, headquartered in the People’s Republic of China....
View Article